Precision BioSciences Inc
PBS0
Company Profile
Business description
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Contact
302 East Pettigrew Street
Dibrell Building, Suite A-100
DurhamNC27701
USAT: +1 919 314-5512
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
102
Stocks News & Analysis
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
stocks
What now for Santos after takeover offer collapses?
Our Fair Value estimate once again reflects the stand-alone business and its growth potential.
stocks
Morningstar initiates coverage on small cap ASX REIT
Coverage of ASX listed REIT as investor interest in property continues to grow.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,061.20 | 61.30 | -0.67% |
| CAC 40 | 7,853.59 | 1.02 | -0.01% |
| DAX 40 | 23,639.41 | 35.12 | -0.15% |
| Dow JONES (US) | 46,315.27 | 172.85 | 0.37% |
| FTSE 100 | 9,216.67 | 11.44 | -0.12% |
| HKSE | 26,545.10 | 106.59 | 0.40% |
| NASDAQ | 22,631.48 | 160.75 | 0.72% |
| Nikkei 225 | 45,045.81 | 143.54 | 0.32% |
| NZX 50 Index | 13,231.66 | 3.23 | -0.02% |
| S&P 500 | 6,664.36 | 32.40 | 0.49% |
| S&P/ASX 200 | 8,773.50 | 75.00 | -0.85% |
| SSE Composite Index | 3,820.09 | 11.57 | -0.30% |